On the public citation graph

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

0 signed · 2840 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

1 of the 200 references listed on this page is in the Retraction Watch database as retracted (export 2026-10-21): 10.1002/14651858.cd002916.pub2 (notice 2013-11-20).

Dataset join, best-effort; this page does not check the publisher record. Retraction Watch data via Crossref Labs, used with credit; OpenCitations Index (CC0) and Meta (CC BY 4.0); dataset doi:10.7910/DVN/WT8VOA (CC BY 4.0).

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2012.5535openalex-snapshot

Effect of an Indwelling Pleural Catheter vs Chest Tube and Talc Pleurodesis for Relieving Dyspnea in Patients With Malignant Pleural Effusion

inferredcites →https://doi.org/10.1001/jama.2014.3314openalex-snapshot

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor

inferredcites →https://doi.org/10.1001/jama.280.17.1485openalex-snapshot

Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain

inferredcites →https://doi.org/10.1001/jama.292.4.470openalex-snapshot

Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1001/jama.295.21.2483openalex-snapshot

Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases

inferredcites →https://doi.org/10.1001/jamaoncol.2015.4921openalex-snapshot

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1002/(sici)1097-0142(19961001)78:7<1470::aid-cncr14>3.0.co;2-xopenalex-snapshot

A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis

inferredcites →https://doi.org/10.1002/14651858.cd002916.pub2openalex-snapshot

Pleurodesis for malignant pleural effusions

inferredcites →https://doi.org/10.1002/14651858.cd003869.pub3openalex-snapshot

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases

inferredcites →https://doi.org/10.1002/14651858.cd004284.pub3openalex-snapshot

Palliative endobronchial brachytherapy for non-small cell lung cancer

inferredcites →https://doi.org/10.1002/14651858.cd004721openalex-snapshot

Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy

inferredcites →https://doi.org/10.1002/14651858.cd006121.pub3openalex-snapshot

Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases

inferredcites →https://doi.org/10.1002/14651858.cd006121.pub4openalex-snapshot

Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases

inferredcites →https://doi.org/10.1002/14651858.cd006716.pub3openalex-snapshot

Interventions for the treatment of metastatic extradural spinal cord compression in adults

inferredcites →https://doi.org/10.1002/14651858.cd009256.pub2openalex-snapshot

Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer

inferredcites →https://doi.org/10.1002/14651858.cd009454.pub2openalex-snapshot

Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases

inferredcites →https://doi.org/10.1002/ana.410330605openalex-snapshot

Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery

inferredcites →https://doi.org/10.1002/cncr.20308openalex-snapshot

Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors

inferredcites →https://doi.org/10.1002/cncr.23063openalex-snapshot

Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first‐line, systemic chemotherapy

inferredcites →https://doi.org/10.1002/cncr.28132openalex-snapshot

Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study

inferredcites →https://doi.org/10.1002/cncr.28217openalex-snapshot

Stereotactic ablative radiotherapy: A potentially curable approach to early stage multiple primary lung cancer

inferredcites →https://doi.org/10.1002/ijc.24855openalex-snapshot

Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970–2007

inferredcites →https://doi.org/10.1002/ijc.27779openalex-snapshot

Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non–small‐cell lung cancer patients

inferredcites →https://doi.org/10.1007/978-0-387-88443-1openalex-snapshot

AJCC Cancer Staging Handbook

inferredcites →https://doi.org/10.1007/978-3-319-40618-3openalex-snapshot

AJCC Cancer Staging Manual

inferredcites →https://doi.org/10.1007/978-3-642-71178-7_8openalex-snapshot

Results of Therapy

inferredcites →https://doi.org/10.1007/978-3-642-85849-9openalex-snapshot

Cancer Incidence in Five Continents

inferredcites →https://doi.org/10.1007/978-3-642-85851-2openalex-snapshot

Cancer Incidence in Five Continents

inferredcites →https://doi.org/10.1007/s00408-012-9399-3openalex-snapshot

Doublet Versus Single Cytotoxic Agent as First-Line Treatment for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

inferredcites →https://doi.org/10.1007/s00520-013-2022-1openalex-snapshot

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

inferredcites →https://doi.org/10.1016/0169-5002(96)85918-6openalex-snapshot

Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials

inferredcites →https://doi.org/10.1016/0895-6111(94)90011-6openalex-snapshot

MRI evaluation of “solitary” brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients

inferredcites →https://doi.org/10.1016/j.acra.2011.10.018openalex-snapshot

Meta-analysis

inferredcites →https://doi.org/10.1016/j.athoracsur.2014.03.028openalex-snapshot

Metastasectomy for Synchronous Solitary Non-Small Cell Lung Cancer Metastases

inferredcites →https://doi.org/10.1016/j.cllc.2014.04.003openalex-snapshot

An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1016/j.clon.2011.11.004openalex-snapshot

Update on the Systematic Review of Palliative Radiotherapy Trials for Bone Metastases

inferredcites →https://doi.org/10.1016/j.critrevonc.2012.03.007openalex-snapshot

Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis

inferredcites →https://doi.org/10.1016/j.critrevonc.2015.03.010openalex-snapshot

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

inferredcites →https://doi.org/10.1016/j.ejca.2007.12.015openalex-snapshot

Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s

inferredcites →https://doi.org/10.1016/j.ejca.2008.10.026openalex-snapshot

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

inferredcites →https://doi.org/10.1016/j.ejca.2014.11.015openalex-snapshot

Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer

inferredcites →https://doi.org/10.1016/j.ejcts.2005.12.025openalex-snapshot

The evidence on the effectiveness of management for malignant pleural effusion: a systematic review

inferredcites →https://doi.org/10.1016/j.ejcts.2010.01.051openalex-snapshot

The effect of a multidisciplinary thoracic malignancy conference on the treatment of patients with lung cancer☆

inferredcites →https://doi.org/10.1016/j.ijrobp.2014.10.024openalex-snapshot

Phase 3 Trials of Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for 1 to 4 Brain Metastases: Individual Patient Data Meta-Analysis

inferredcites →https://doi.org/10.1016/j.jtho.2015.09.009openalex-snapshot

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

inferredcites →https://doi.org/10.1016/j.jtho.2015.11.014openalex-snapshot

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

inferredcites →https://doi.org/10.1016/j.jtho.2015.12.111openalex-snapshot

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm

inferredcites →https://doi.org/10.1016/j.jtho.2016.01.025openalex-snapshot

The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

inferredcites →https://doi.org/10.1016/j.jtho.2016.03.019openalex-snapshot

A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer

inferredcites →https://doi.org/10.1016/j.lungcan.2005.11.001openalex-snapshot

Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials

inferredcites →https://doi.org/10.1016/j.lungcan.2007.03.014openalex-snapshot

A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer

inferredcites →https://doi.org/10.1016/j.lungcan.2007.07.012openalex-snapshot

Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials

inferredcites →https://doi.org/10.1016/j.lungcan.2010.03.003openalex-snapshot

Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study)

inferredcites →https://doi.org/10.1016/j.lungcan.2011.11.012openalex-snapshot

Carcinoembryonic antigen (CEA) as tumor marker in lung cancer

inferredcites →https://doi.org/10.1016/j.lungcan.2014.03.026openalex-snapshot

Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: A meta-analysis of randomized controlled clinical trials

inferredcites →https://doi.org/10.1016/j.radonc.2006.08.024openalex-snapshot

Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: Results and toxicity

inferredcites →https://doi.org/10.1016/j.radonc.2013.04.026openalex-snapshot

Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery

inferredcites →https://doi.org/10.1016/s0009-9260(99)91181-9openalex-snapshot

Imaging features of leptomeningeal metastases

inferredcites →https://doi.org/10.1016/s0012-3692(15)50902-1openalex-snapshot

Smoking Cessation After Diagnosis of Lung Cancer Is Associated With a Beneficial Effect on Performance Status

inferredcites →https://doi.org/10.1016/s0140-6736(04)16250-8openalex-snapshot

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial

inferredcites →https://doi.org/10.1016/s0140-6736(08)61758-4openalex-snapshot

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

inferredcites →https://doi.org/10.1016/s0140-6736(09)60569-9openalex-snapshot

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

inferredcites →https://doi.org/10.1016/s0140-6736(09)61497-5openalex-snapshot

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

inferredcites →https://doi.org/10.1016/s0140-6736(11)60780-0openalex-snapshot

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

inferredcites →https://doi.org/10.1016/s0140-6736(14)60845-xopenalex-snapshot

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

inferredcites →https://doi.org/10.1016/s0140-6736(15)01281-7openalex-snapshot

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

inferredcites →https://doi.org/10.1016/s0140-6736(16)00004-0openalex-snapshot

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

inferredcites →https://doi.org/10.1016/s0169-5002(02)00183-6openalex-snapshot

A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis

inferredcites →https://doi.org/10.1016/s1470-2045(07)70246-2openalex-snapshot

Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data

inferredcites →https://doi.org/10.1016/s1470-2045(09)70364-xopenalex-snapshot

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

inferredcites →https://doi.org/10.1016/s1470-2045(10)70112-1openalex-snapshot

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

inferredcites →https://doi.org/10.1016/s1470-2045(11)70232-7openalex-snapshot

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

inferredcites →https://doi.org/10.1016/s1470-2045(11)70385-0openalex-snapshot

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

inferredcites →https://doi.org/10.1016/s1470-2045(11)70393-xopenalex-snapshot

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

inferredcites →https://doi.org/10.1016/s1470-2045(12)70063-3openalex-snapshot

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

inferredcites →https://doi.org/10.1016/s1470-2045(12)70344-3openalex-snapshot

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

inferredcites →https://doi.org/10.1016/s1470-2045(13)70310-3openalex-snapshot

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

inferredcites →https://doi.org/10.1016/s1470-2045(13)70586-2openalex-snapshot

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

inferredcites →https://doi.org/10.1016/s1470-2045(13)70604-1openalex-snapshot

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

inferredcites →https://doi.org/10.1016/s1470-2045(14)70061-0openalex-snapshot

Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study

inferredcites →https://doi.org/10.1016/s1470-2045(14)70381-xopenalex-snapshot

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

inferredcites →https://doi.org/10.1016/s1470-2045(14)70402-4openalex-snapshot

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data

inferredcites →https://doi.org/10.1016/s1470-2045(14)71173-8openalex-snapshot

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

inferredcites →https://doi.org/10.1016/s1470-2045(15)00006-6openalex-snapshot

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

inferredcites →https://doi.org/10.1016/s1470-2045(15)00021-2openalex-snapshot

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

inferredcites →https://doi.org/10.1016/s1470-2045(15)00121-7openalex-snapshot

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

inferredcites →https://doi.org/10.1016/s1470-2045(15)00488-xopenalex-snapshot

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

inferredcites →https://doi.org/10.1016/s1470-2045(15)00614-2openalex-snapshot

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

inferredcites →https://doi.org/10.1016/s1470-2045(15)70046-xopenalex-snapshot

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

inferredcites →https://doi.org/10.1016/s1470-2045(15)70054-9openalex-snapshot

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

inferredcites →https://doi.org/10.1016/s1470-2045(16)30033-xopenalex-snapshot

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

inferredcites →https://doi.org/10.1016/s1556-0864(16)30326-4openalex-snapshot

1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV…

inferredcites →https://doi.org/10.1016/s1556-0864(16)30328-8openalex-snapshot

135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC

inferredcites →https://doi.org/10.1023/a:1008338312647openalex-snapshot

Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1

inferredcites →https://doi.org/10.1038/bjc.2013.721openalex-snapshot

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

inferredcites →https://doi.org/10.1038/nature06885openalex-snapshot

A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25

inferredcites →https://doi.org/10.1038/nbt.2696openalex-snapshot

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

inferredcites →https://doi.org/10.1038/ng.273openalex-snapshot

Common 5p15.33 and 6p21.33 variants influence lung cancer risk

inferredcites →https://doi.org/10.1038/nrclinonc.2014.96openalex-snapshot

The oligometastatic state—separating truth from wishful thinking

inferredcites →https://doi.org/10.1038/sj.bjc.6602241openalex-snapshot

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study

inferredcites →https://doi.org/10.1038/sj.bjc.6602825openalex-snapshot

An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer

inferredcites →https://doi.org/10.1055/s-0034-1377060openalex-snapshot

Surgery of Primary Lung Cancer with Oligometastatic M1b Synchronous Single Brain Metastasis: Analysis of 37 Cases

inferredcites →https://doi.org/10.1056/nejm199002223220802openalex-snapshot

A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain

inferredcites →https://doi.org/10.1056/nejmoa011954openalex-snapshot

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1056/nejmoa040938openalex-snapshot

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

inferredcites →https://doi.org/10.1056/nejmoa050753openalex-snapshot

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1056/nejmoa061884openalex-snapshot

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1056/nejmoa0810699openalex-snapshot

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

inferredcites →https://doi.org/10.1056/nejmoa0904554openalex-snapshot

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

inferredcites →https://doi.org/10.1056/nejmoa0909530openalex-snapshot

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

inferredcites →https://doi.org/10.1056/nejmoa1000678openalex-snapshot

Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1056/nejmoa1006448openalex-snapshot

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1056/nejmoa1214886openalex-snapshot

Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

inferredcites →https://doi.org/10.1056/nejmoa1408440openalex-snapshot

First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer

inferredcites →https://doi.org/10.1056/nejmoa1411817openalex-snapshot

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1056/nejmoa1504627openalex-snapshot

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1056/nejmoa1507643openalex-snapshot

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1073/pnas.0709662105openalex-snapshot

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

inferredcites →https://doi.org/10.1086/321805openalex-snapshot

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

inferredcites →https://doi.org/10.1093/annonc/mdh087openalex-snapshot

Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel

inferredcites →https://doi.org/10.1093/annonc/mds214openalex-snapshot

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

inferredcites →https://doi.org/10.1093/annonc/mds461openalex-snapshot

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

inferredcites →https://doi.org/10.1093/annonc/mds590openalex-snapshot

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

inferredcites →https://doi.org/10.1093/annonc/mdu098openalex-snapshot

Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

inferredcites →https://doi.org/10.1093/annonc/mdu145openalex-snapshot

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

inferredcites →https://doi.org/10.1093/annonc/mdu584openalex-snapshot

A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer

inferredcites →https://doi.org/10.1093/annonc/mdv001openalex-snapshot

European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?

inferredcites →https://doi.org/10.1093/annonc/mdv249openalex-snapshot

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

inferredcites →https://doi.org/10.1093/annonc/mdv550openalex-snapshot

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

inferredcites →https://doi.org/10.1093/jnci/91.1.66openalex-snapshot

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1093/jnci/94.3.173openalex-snapshot

Cisplatin-Based Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Implications of Eastern Cooperative Oncology Group 5592, a Randomized Trial

inferredcites →https://doi.org/10.1093/jnci/95.5.362openalex-snapshot

Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial

inferredcites →https://doi.org/10.1093/jnci/djk196openalex-snapshot

Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis

inferredcites →https://doi.org/10.1097/jto.0000000000000318openalex-snapshot

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1097/jto.0000000000000643openalex-snapshot

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients

inferredcites →https://doi.org/10.1097/jto.0000000000000673openalex-snapshot

The IASLC Lung Cancer Staging Project

inferredcites →https://doi.org/10.1097/jto.0b013e31811f4703openalex-snapshot

The IASLC Lung Cancer Staging Project: Proposals for Revision of the M Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer

inferredcites →https://doi.org/10.1097/jto.0b013e3181a9a020openalex-snapshot

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials

inferredcites →https://doi.org/10.1097/jto.0b013e3181e95cb8openalex-snapshot

Prognostic Factors for Survival after Surgical Palliation of Malignant Pleural Effusion

inferredcites →https://doi.org/10.1097/jto.0b013e3181f77b58openalex-snapshot

Treatment of Lung Cancer with an ALK Inhibitor After EML4-ALK Fusion Gene Detection Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration

inferredcites →https://doi.org/10.1097/jto.0b013e31820517a3openalex-snapshot

Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing

inferredcites →https://doi.org/10.1097/jto.0b013e318206a221openalex-snapshot

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

inferredcites →https://doi.org/10.1097/jto.0b013e318220c912openalex-snapshot

Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal Staging in Non-small Cell Lung Cancer: Results of Mediastinal Staging in the Early Lung Positron Emission Tomography Trial

inferredcites →https://doi.org/10.1097/jto.0b013e318262caf6openalex-snapshot

Radical Treatment of Non–Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450)

inferredcites →https://doi.org/10.1097/jto.0b013e31826aec2bopenalex-snapshot

Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

inferredcites →https://doi.org/10.1097/jto.0b013e3182745948openalex-snapshot

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1097/jto.0b013e318290868fopenalex-snapshot

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

inferredcites →https://doi.org/10.1111/ajco.12192openalex-snapshot

Impact of the lung oncology multidisciplinary team meetings on the management of patients with cancer

inferredcites →https://doi.org/10.1111/cas.12847openalex-snapshot

Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study

inferredcites →https://doi.org/10.1111/j.1539-6924.2012.01768.xopenalex-snapshot

Chapter 6: Lung Cancer in Never Smokers: Epidemiology and Risk Prediction Models

inferredcites →https://doi.org/10.1126/science.1099314openalex-snapshot

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

inferredcites →https://doi.org/10.1126/scitranslmed.3002003openalex-snapshot

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

inferredcites →https://doi.org/10.1136/bmj.311.7010.899openalex-snapshot

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

inferredcites →https://doi.org/10.1136/bmjspcare-2013-000589openalex-snapshot

Quality of life, support and smoking in advanced lung cancer patients: a qualitative study

inferredcites →https://doi.org/10.1136/bmjspcare-2015-000957openalex-snapshot

Treatment with bone-seeking radionuclides for painful bone metastases in patients with lung cancer: a systematic review

inferredcites →https://doi.org/10.1136/thx.2008.109868openalex-snapshot

Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis

inferredcites →https://doi.org/10.1158/1055-9965.epi-05-0201openalex-snapshot

Familial Lung Cancer and Aggregation of Smoking Habits: A Simulation of the Effect of Shared Environmental Factors on the Familial Risk of Cancer

inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-1624openalex-snapshot

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

inferredcites →https://doi.org/10.1158/1078-0432.ccr-10-0099openalex-snapshot

EML4-ALK Fusion Gene Assessment Using Metastatic Lymph Node Samples Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration

inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-2109openalex-snapshot

Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR / KRA S and Presence of PIK3CA / AKT1 Mutations

inferredcites →https://doi.org/10.1158/1078-0432.ccr-12-2246openalex-snapshot

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers

inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-0895openalex-snapshot

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-2791openalex-snapshot

Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine

inferredcites →https://doi.org/10.1158/1535-7163.mct-15-0582openalex-snapshot

Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma

inferredcites →https://doi.org/10.1158/2159-8290.cd-12-0387openalex-snapshot

Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance

inferredcites →https://doi.org/10.1183/09031936.00097214openalex-snapshot

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

inferredcites →https://doi.org/10.1183/09059180.00004614openalex-snapshot

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas

inferredcites →https://doi.org/10.1186/2051-1426-2-17openalex-snapshot

Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

inferredcites →https://doi.org/10.1200/jco.1995.13.1.8openalex-snapshot

Oligometastases.

inferredcites →https://doi.org/10.1200/jco.2000.18.10.2095openalex-snapshot

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

inferredcites →https://doi.org/10.1200/jco.2000.18.12.2354openalex-snapshot

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

inferredcites →https://doi.org/10.1200/jco.2004.08.163openalex-snapshot

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

inferredcites →https://doi.org/10.1200/jco.2005.02.3739openalex-snapshot

Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel

inferredcites →https://doi.org/10.1200/jco.2005.03.045openalex-snapshot

Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature

inferredcites →https://doi.org/10.1200/jco.2005.04.8033openalex-snapshot

Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity

inferredcites →https://doi.org/10.1200/jco.2005.05.4692openalex-snapshot

Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

inferredcites →https://doi.org/10.1200/jco.2006.06.1044openalex-snapshot

Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

inferredcites →https://doi.org/10.1200/jco.2006.09.2536openalex-snapshot

Regression After Whole-Brain Radiation Therapy for Brain Metastases Correlates With Survival and Improved Neurocognitive Function

inferredcites →https://doi.org/10.1200/jco.2007.10.6559openalex-snapshot

Comprehensive Geriatric Assessment for Older Patients With Cancer

inferredcites →https://doi.org/10.1200/jco.2007.10.8134openalex-snapshot

Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1200/jco.2007.14.5466openalex-snapshot

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

inferredcites →https://doi.org/10.1200/jco.2007.14.8494openalex-snapshot

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

inferredcites →https://doi.org/10.1200/jco.2007.15.0375openalex-snapshot

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1200/jco.2008.17.1405openalex-snapshot

Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1200/jco.2008.17.5844openalex-snapshot

Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1200/jco.2008.17.7162openalex-snapshot

Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials

inferredcites →https://doi.org/10.1200/jco.2008.18.7658openalex-snapshot

First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy

inferredcites →https://doi.org/10.1200/jco.2008.19.3995openalex-snapshot

Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers

inferredcites →https://doi.org/10.1200/jco.2009.22.6993openalex-snapshot

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.8016openalex-snapshot

First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group

inferredcites →https://doi.org/10.1200/jco.2010.28.15_suppl.9075openalex-snapshot

The association between clinical, sociodemographic, and logistic-administrative factors and adherence to completing health-related quality-of-life questionnaires.

inferredcites →https://doi.org/10.1200/jco.2010.30.1655openalex-snapshot

Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study

inferredcites →https://doi.org/10.1200/jco.2010.31.3304openalex-snapshot

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

inferredcites →https://doi.org/10.1200/jco.2010.33.1280openalex-snapshot

Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations

inferredcites →https://doi.org/10.1200/jco.2010.34.1313openalex-snapshot

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

inferredcites →https://doi.org/10.1200/jco.2011.36.8456openalex-snapshot

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

inferredcites →https://doi.org/10.1200/jco.2011.38.0527openalex-snapshot

Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases

inferredcites →https://doi.org/10.1200/jco.2011.39.5848openalex-snapshot

Weekly nab -Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

inferredcites →https://doi.org/10.1200/jco.2012.42.3749openalex-snapshot

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

inferredcites →https://doi.org/10.1200/jco.2012.42.6098openalex-snapshot

Increasing Lung Cancer Death Rates Among Young Women in Southern and Midwestern States

showing the first 200 of 232

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4654986openalex-extracted

Joint Forces of Mass Spectrometric Techniques (Icp-Ms and Maldi-Tof-Ms) and Fluorescence Spectrometry in the Study of Platinum-Based Cytostatic Drugs Interactions with Metallothionein Mt2 and Mt3

inferred← citeshttps://doi.org/10.1001/jama.2014.3314openalex-snapshot

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor

inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.0775openalex-snapshot

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma

inferred← citeshttps://doi.org/10.1001/jamaoncol.2020.0409openalex-snapshot

Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer

inferred← citeshttps://doi.org/10.1001/jamaoncol.2022.5959openalex-snapshot

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden

inferred← citeshttps://doi.org/10.1001/jamaoncol.2022.6109openalex-snapshot

Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non–Small Cell Lung Cancer

inferred← citeshttps://doi.org/10.1001/jamaoncol.2023.3867openalex-snapshot

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors

inferred← citeshttps://doi.org/10.1002/14651858.cd010383.pub3openalex-snapshot

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

inferred← citeshttps://doi.org/10.1002/14651858.cd012901openalex-snapshot

Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second-line treatment for non-small-cell lung cancer wild-type or unknown status for EGFR

inferred← citeshttps://doi.org/10.1002/14651858.cd013009openalex-snapshot

Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol

inferred← citeshttps://doi.org/10.1002/14651858.cd013075openalex-snapshot

Taxanes for advanced non-small cell lung cancer

inferred← citeshttps://doi.org/10.1002/14651858.cd013257openalex-snapshot

Single or combined immune checkpoint inhibitors compared to first-line chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer

inferred← citeshttps://doi.org/10.1002/14651858.cd013257.pub2openalex-snapshot

Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer

inferred← citeshttps://doi.org/10.1002/14651858.cd013257.pub3openalex-snapshot

Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer

inferred← citeshttps://doi.org/10.1002/14651858.cd013382openalex-snapshot

Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

inferred← citeshttps://doi.org/10.1002/14651858.cd013453openalex-snapshot

Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer

inferred← citeshttps://doi.org/10.1002/14651858.cd013453.pub2openalex-snapshot

Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer

inferred← citeshttps://doi.org/10.1002/14651858.cd014907.pub2openalex-snapshot

Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol

inferred← citeshttps://doi.org/10.1002/14651858.cd015495openalex-snapshot

Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer

inferred← citeshttps://doi.org/10.1002/1878-0261.12546openalex-snapshot

Intra‐individual variation of circulating tumour DNA in lung cancer patients

inferred← citeshttps://doi.org/10.1002/1878-0261.12889openalex-snapshot

Discovery and validation of extracellular vesicle‐associated miRNAs as noninvasive detection biomarkers for early‐stage non‐small‐cell lung cancer

inferred← citeshttps://doi.org/10.1002/1878-0261.12891openalex-snapshot

Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer

inferred← citeshttps://doi.org/10.1002/1878-0261.12976openalex-snapshot

Unveiling mutational dynamics in non‐small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA

inferred← citeshttps://doi.org/10.1002/1878-0261.13094openalex-snapshot

Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non‐small‐cell lung cancer treated with pembrolizumab

inferred← citeshttps://doi.org/10.1002/1878-0261.13550openalex-snapshot

Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications

inferred← citeshttps://doi.org/10.1002/1878-0261.13562openalex-snapshot

A scenario‐drafting study to explore potential future implementation pathways of circulating tumor DNA testing in oncology

inferred← citeshttps://doi.org/10.1002/2211-5463.12738openalex-snapshot

MicroRNA‐7‐5p induces cell growth inhibition, cell cycle arrest and apoptosis by targeting PAK2 in non‐small cell lung cancer

inferred← citeshttps://doi.org/10.1002/bmc.5277openalex-snapshot

Highly sensitive quantification of pemetrexed in human plasma using UPLC‐MS/MS to support microdosing studies

inferred← citeshttps://doi.org/10.1002/cam4.2652openalex-snapshot

Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study

inferred← citeshttps://doi.org/10.1002/cam4.2882openalex-snapshot

Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer

inferred← citeshttps://doi.org/10.1002/cam4.3639openalex-snapshot

Suppression of tumor immune microenvironment via microRNA‐1 after epidermal growth factor receptor‐tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma

inferred← citeshttps://doi.org/10.1002/cam4.4160openalex-snapshot

A clinical variable‐based nomogram could predict the survival for advanced NSCLC patients receiving second‐line atezolizumab

inferred← citeshttps://doi.org/10.1002/cam4.4192openalex-snapshot

EGFR‐mutated stage IV non‐small cell lung cancer: What is the role of radiotherapy combined with TKI?

inferred← citeshttps://doi.org/10.1002/cam4.4310openalex-snapshot

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study

inferred← citeshttps://doi.org/10.1002/cam4.4405openalex-snapshot

First‐line immune‐based combination therapies for advanced non‐small cell lung cancer: A Bayesian network meta‐analysis

inferred← citeshttps://doi.org/10.1002/cam4.4798openalex-snapshot

Cost‐effectiveness of osimertinib versus placebo in resected EGFR ‐mutated non‐small cell lung cancer in China

inferred← citeshttps://doi.org/10.1002/cam4.5658openalex-snapshot

Assessment of survival outcomes among lung cancer patients at the National and Referral Hospital in Kenya

inferred← citeshttps://doi.org/10.1002/cam4.5960openalex-snapshot

Ginsenoside Rh2 attenuates the progression of non‐small cell lung cancer by sponging miR ‐28‐5p/ STK4 axis and inactivating Wnt/β‐catenin signaling

inferred← citeshttps://doi.org/10.1002/cam4.6135openalex-snapshot

Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321

inferred← citeshttps://doi.org/10.1002/cam4.6405openalex-snapshot

Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR ‐mutated NSCLC

inferred← citeshttps://doi.org/10.1002/cam4.6478openalex-snapshot

Efficacy and safety of reduced‐dose chemotherapy plus immunotherapy in patients with lung squamous cell carcinoma: A real‐world observational study

inferred← citeshttps://doi.org/10.1002/cam4.6664openalex-snapshot

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study

inferred← citeshttps://doi.org/10.1002/cam4.71975openalex-snapshot

Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France

inferred← citeshttps://doi.org/10.1002/cam4.7208openalex-snapshot

Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study

inferred← citeshttps://doi.org/10.1002/cdt3.19openalex-snapshot

The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer

inferred← citeshttps://doi.org/10.1002/cjp2.153openalex-snapshot

External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different

inferred← citeshttps://doi.org/10.1002/cncr.26496openalex-snapshot

Innovative cancer therapies

inferred← citeshttps://doi.org/10.1002/cncr.29571openalex-snapshot

Chinese consensus on early diagnosis of primary lung cancer (2014 version)

inferred← citeshttps://doi.org/10.1002/cncr.31055openalex-snapshot

Implementation of precision medicine in clinical trials in thoracic oncology: Which are the hurdles?

inferred← citeshttps://doi.org/10.1002/cncr.31891openalex-snapshot

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

inferred← citeshttps://doi.org/10.1002/cncr.32987openalex-snapshot

A randomized phase 3 study of maintenance therapy with S‐1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S‐1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L)

inferred← citeshttps://doi.org/10.1002/cncr.33159openalex-snapshot

The METeoric rise of MET in lung cancer

inferred← citeshttps://doi.org/10.1002/cncr.33571openalex-snapshot

High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program

inferred← citeshttps://doi.org/10.1002/cncr.33984openalex-snapshot

Long‐term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real‐world data (KCSG LU20‐11)

inferred← citeshttps://doi.org/10.1002/cncr.34113openalex-snapshot

Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer

inferred← citeshttps://doi.org/10.1002/cncr.34683openalex-snapshot

Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer

inferred← citeshttps://doi.org/10.1002/cncy.21426openalex-snapshot

Molecular testing in lung cancer: Fine‐needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication

inferred← citeshttps://doi.org/10.1002/cncy.22383openalex-snapshot

Formalin fixation for optimal concordance of programmed death‐ligand 1 immunostaining between cytologic and histologic specimens from patients with non–small cell lung cancer

inferred← citeshttps://doi.org/10.1002/cncy.22400openalex-snapshot

Tumor mutational burden on cytological samples: A pilot study

inferred← citeshttps://doi.org/10.1002/cnr2.1487openalex-snapshot

Real‐world experience of nivolumab in the treatment of poor performance status patients with advanced non‐small cell lung cancer

inferred← citeshttps://doi.org/10.1002/cnr2.1544openalex-snapshot

EGFR ‐plasma mutations in prognosis for non‐small cell lung cancer treated with EGFR TKIs : A meta‐analysis

inferred← citeshttps://doi.org/10.1002/cpdd.1095openalex-snapshot

Effect of Food Intake on Pharmacokinetics of Oral Almonertinib: A Randomized Crossover Trial in Healthy Chinese Participants

inferred← citeshttps://doi.org/10.1002/cpdd.1483openalex-snapshot

Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation‐Positive Advanced Non–Small‐Cell Lung Cancer: A Meta‐Analysis

inferred← citeshttps://doi.org/10.1002/ctm2.70374openalex-snapshot

Interleukin‐11 promotes lung adenocarcinoma tumourigenesis and immune evasion

inferred← citeshttps://doi.org/10.1002/ctm2.882openalex-snapshot

Genome‐wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild‐type TP53 and receptor tyrosine kinase genes

inferred← citeshttps://doi.org/10.1002/dc.24856openalex-snapshot

EGFR analysis on scrapings from cytology smears in lung carcinoma, an effective alternative to testing on trucut biopsies

inferred← citeshttps://doi.org/10.1002/ijc.31136openalex-snapshot

Looking for the best immune‐checkpoint inhibitor in pre‐treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab

inferred← citeshttps://doi.org/10.1002/ijc.31175openalex-snapshot

Bevacizumab in combination with different platinum‐based doublets in the first‐line treatment for advanced nonsquamous non‐small‐cell lung cancer: A network meta‐analysis

inferred← citeshttps://doi.org/10.1002/ijc.32133openalex-snapshot

Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases

inferred← citeshttps://doi.org/10.1002/ijc.32358openalex-snapshot

Variant classification in precision oncology

inferred← citeshttps://doi.org/10.1002/ijc.32366openalex-snapshot

PD‐(L)1 inhibitors vs. chemotherapy vs. their combination in front‐line treatment for NSCLC: An indirect comparison

inferred← citeshttps://doi.org/10.1002/ijc.33853openalex-snapshot

In‐depth molecular analysis of combined and co‐primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma

inferred← citeshttps://doi.org/10.1002/jbt.23269openalex-snapshot

Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum‐based doublet chemotherapy

inferred← citeshttps://doi.org/10.1002/jcla.23141openalex-snapshot

RETRACTED: Katanin P80 correlates with larger tumor size, lymph node metastasis, and advanced TNM stage and predicts poor prognosis in non–small‐cell lung cancer patients

inferred← citeshttps://doi.org/10.1002/jcp.29371openalex-snapshot

The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis

inferred← citeshttps://doi.org/10.1002/jcp.30561openalex-snapshot

The multidimensional role of the Wnt/β‐catenin signaling pathway in human malignancies

inferred← citeshttps://doi.org/10.1002/jcph.1042openalex-snapshot

Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study

inferred← citeshttps://doi.org/10.1002/jcsm.12698openalex-snapshot

The prognostic value of weight and body composition changes in patients with non‐small‐cell lung cancer treated with nivolumab

inferred← citeshttps://doi.org/10.1002/mco2.152openalex-snapshot

Glutathione peroxidase 8 expression on cancer cells and cancer‐associated fibroblasts facilitates lung cancer metastasis

inferred← citeshttps://doi.org/10.1002/mco2.483openalex-snapshot

Genome‐scale CRISPR–Cas9 screen identifies PAICS as a therapeutic target for EGFR wild‐type non‐small cell lung cancer

inferred← citeshttps://doi.org/10.1002/mco2.644openalex-snapshot

Development of a genome atlas for discriminating benign, preinvasive, and invasive lung nodules

inferred← citeshttps://doi.org/10.1002/mp.14529openalex-snapshot

A method for predictive modeling of tumor regression for lung adaptive radiotherapy

inferred← citeshttps://doi.org/10.1002/onco.13586openalex-snapshot

Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach

inferred← citeshttps://doi.org/10.1002/onco.13745openalex-snapshot

Novel SLC12A2-ROS1 Fusion in Non-Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next-Generation Sequencing Assay

inferred← citeshttps://doi.org/10.1002/onco.13840openalex-snapshot

Surgical Metastasectomy in the Spine: A Review Article

inferred← citeshttps://doi.org/10.1002/onco.13909openalex-snapshot

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Real-World Data from an Academic Central and Eastern European Center

inferred← citeshttps://doi.org/10.1002/path.5038openalex-snapshot

Established, emerging and elusive molecular targets in the treatment of lung cancer

inferred← citeshttps://doi.org/10.1002/psp4.12937openalex-snapshot

A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients

inferred← citeshttps://doi.org/10.1002/smtd.201900357openalex-snapshot

CLAmp‐seq: A Novel Amplicon‐Based NGS Assay with Concatemer Error Correction for Improved Detection of Actionable Mutations in Plasma cfDNA from Patients with NSCLC

inferred← citeshttps://doi.org/10.1007/164_2017_16openalex-snapshot

Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer

inferred← citeshttps://doi.org/10.1007/978-1-4939-0727-4_24openalex-snapshot

Genomic Applications in Pulmonary Malignancies

inferred← citeshttps://doi.org/10.1007/978-1-4939-2047-1_9openalex-snapshot

Targeted Therapies for Non-Small Cell Lung Cancer

inferred← citeshttps://doi.org/10.1007/978-2-8178-0021-9_15openalex-snapshot

Cancer bronchique non à petites cellules

inferred← citeshttps://doi.org/10.1007/978-3-030-27233-3_2openalex-snapshot

Radiological Signs of Tumor Dissemination

inferred← citeshttps://doi.org/10.1007/978-3-030-39457-8_21openalex-snapshot

PET in Lung Cancer and Mediastinal Malignancies

inferred← citeshttps://doi.org/10.1007/978-3-030-47404-1_23openalex-snapshot

Does Local Therapy for Oligometastatic Disease in Lung Cancer Patients Improve Survival?

inferred← citeshttps://doi.org/10.1007/978-3-030-47404-1_6openalex-snapshot

EBUS vs. Mediastinoscopy for Initial Pathologic Mediastinal Staging in NSCLC

inferred← citeshttps://doi.org/10.1007/978-3-030-56051-5_32openalex-snapshot

Lung Cancer

inferred← citeshttps://doi.org/10.1007/978-3-030-60429-5_6openalex-snapshot

PET Beyond Pictures

inferred← citeshttps://doi.org/10.1007/978-3-030-78079-1_7openalex-snapshot

Image-Guided Brachytherapy in Oligometastasis: Criteria for Patient Selection from an Oncological Perspective

inferred← citeshttps://doi.org/10.1007/978-3-030-81788-6_12openalex-snapshot

The Role of Palliative Care in Lung Cancer

inferred← citeshttps://doi.org/10.1007/978-3-030-85292-4_18openalex-snapshot

Machine Learning-Based Radiomics in Neuro-Oncology

inferred← citeshttps://doi.org/10.1007/978-3-031-71477-1_15openalex-snapshot

Neurosurgery for the Elderly

inferred← citeshttps://doi.org/10.1007/978-3-319-31215-6_22-1openalex-snapshot

Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer

inferred← citeshttps://doi.org/10.1007/978-3-319-33673-2_22openalex-snapshot

Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer

inferred← citeshttps://doi.org/10.1007/978-3-319-52619-5_34-1openalex-snapshot

Radiation Therapy in Non-small-Cell Lung Cancer

inferred← citeshttps://doi.org/10.1007/978-3-319-58036-4_20openalex-snapshot

Lung Cancer Epidemiologic Changes: Implications in Diagnosis and Therapy

inferred← citeshttps://doi.org/10.1007/978-3-319-70253-7_3openalex-snapshot

Lung Cancer

inferred← citeshttps://doi.org/10.1007/978-3-319-89893-3_3openalex-snapshot

PET Hybrid Imaging of the Thorax

inferred← citeshttps://doi.org/10.1007/978-3-319-91442-8_18openalex-snapshot

Osimertinib

inferred← citeshttps://doi.org/10.1007/978-3-319-96830-8_27openalex-snapshot

Genomic Applications in Pulmonary Malignancies

inferred← citeshttps://doi.org/10.1007/978-3-662-48727-3_38openalex-snapshot

Lungenkarzinom beim alten und geriatrischen Patienten

inferred← citeshttps://doi.org/10.1007/978-3-662-49083-9_38-1openalex-snapshot

Lungenkarzinom beim alten und geriatrischen Patienten

inferred← citeshttps://doi.org/10.1007/978-981-10-6469-2_1openalex-snapshot

Molecular Diagnosis and Targeting for Lung Cancer

inferred← citeshttps://doi.org/10.1007/978-981-15-5120-8_18openalex-snapshot

Cancer Stem Cells in Patient Survival and Therapies in Cancer

inferred← citeshttps://doi.org/10.1007/s00228-014-1662-5openalex-snapshot

Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study

inferred← citeshttps://doi.org/10.1007/s00234-020-02529-2openalex-snapshot

Diffusion tensor and postcontrast T1-weighted imaging radiomics to differentiate the epidermal growth factor receptor mutation status of brain metastases from non-small cell lung cancer

inferred← citeshttps://doi.org/10.1007/s00259-016-3407-4openalex-snapshot

Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer

inferred← citeshttps://doi.org/10.1007/s00259-017-3885-zopenalex-snapshot

Value of 18F–FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients

inferred← citeshttps://doi.org/10.1007/s00259-018-4109-xopenalex-snapshot

Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer

inferred← citeshttps://doi.org/10.1007/s00259-019-04285-9openalex-snapshot

Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up]

inferred← citeshttps://doi.org/10.1007/s00259-021-05242-1openalex-snapshot

Structural and functional radiomics for lung cancer

inferred← citeshttps://doi.org/10.1007/s00259-021-05371-7openalex-snapshot

Radiomics and gene expression profile to characterise the disease and predict outcome in patients with lung cancer

inferred← citeshttps://doi.org/10.1007/s00259-022-05788-8openalex-snapshot

Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer

inferred← citeshttps://doi.org/10.1007/s00259-024-06794-8openalex-snapshot

[18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal

inferred← citeshttps://doi.org/10.1007/s00262-019-02310-2openalex-snapshot

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors

inferred← citeshttps://doi.org/10.1007/s00262-019-02367-zopenalex-snapshot

Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study

inferred← citeshttps://doi.org/10.1007/s00262-020-02757-8openalex-snapshot

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2

inferred← citeshttps://doi.org/10.1007/s00262-021-02981-wopenalex-snapshot

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma

inferred← citeshttps://doi.org/10.1007/s00262-021-03031-1openalex-snapshot

Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials

inferred← citeshttps://doi.org/10.1007/s00262-021-03089-xopenalex-snapshot

First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis

inferred← citeshttps://doi.org/10.1007/s00262-021-03108-xopenalex-snapshot

Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab

inferred← citeshttps://doi.org/10.1007/s00262-022-03359-2openalex-snapshot

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

inferred← citeshttps://doi.org/10.1007/s00262-024-03932-xopenalex-snapshot

Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial

inferred← citeshttps://doi.org/10.1007/s00270-019-02222-9openalex-snapshot

Focus on Recommendations for the Management of Non-small Cell Lung Cancer

inferred← citeshttps://doi.org/10.1007/s00270-020-02432-6openalex-snapshot

CIRSE Standards of Practice on Thermal Ablation of Primary and Secondary Lung Tumours

inferred← citeshttps://doi.org/10.1007/s00270-020-02480-yopenalex-snapshot

Multi-Level Vertebroplasty for 6 or More Painful Osteoporotic Vertebral Body Compression Fractures Performed in the Same Procedural Setting: A Safety and Efficacy Report in Cancer Patients

inferred← citeshttps://doi.org/10.1007/s00280-011-1685-xopenalex-snapshot

Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors

inferred← citeshttps://doi.org/10.1007/s00280-012-1833-yopenalex-snapshot

Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials

inferred← citeshttps://doi.org/10.1007/s00280-012-1910-2openalex-snapshot

Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902

inferred← citeshttps://doi.org/10.1007/s00280-012-1965-0openalex-snapshot

A biomarker profile for predicting efficacy of cisplatin–vinorelbine therapy in malignant pleural mesothelioma

inferred← citeshttps://doi.org/10.1007/s00280-013-2142-9openalex-snapshot

Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901

inferred← citeshttps://doi.org/10.1007/s00280-015-2896-3openalex-snapshot

Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer

inferred← citeshttps://doi.org/10.1007/s00280-015-2950-1openalex-snapshot

A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients

inferred← citeshttps://doi.org/10.1007/s00280-016-2969-yopenalex-snapshot

Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance

inferred← citeshttps://doi.org/10.1007/s00280-017-3516-1openalex-snapshot

First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?

inferred← citeshttps://doi.org/10.1007/s00280-018-3596-6openalex-snapshot

Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR–TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations

inferred← citeshttps://doi.org/10.1007/s00280-018-3649-xopenalex-snapshot

An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy

inferred← citeshttps://doi.org/10.1007/s00280-019-03794-6openalex-snapshot

ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study

inferred← citeshttps://doi.org/10.1007/s00280-019-04008-9openalex-snapshot

Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients

inferred← citeshttps://doi.org/10.1007/s00280-021-04230-4openalex-snapshot

Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors

inferred← citeshttps://doi.org/10.1007/s00280-021-04362-7openalex-snapshot

Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case–control study

inferred← citeshttps://doi.org/10.1007/s00280-022-04447-xopenalex-snapshot

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship

inferred← citeshttps://doi.org/10.1007/s00280-023-04558-zopenalex-snapshot

External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data

inferred← citeshttps://doi.org/10.1007/s00280-024-04647-7openalex-snapshot

Pharmacokinetics, mass balance, and metabolism of [14C]envonalkib (TQ-B3139), a novel ALK tyrosine kinase inhibitor, in healthy Chinese subjects

inferred← citeshttps://doi.org/10.1007/s00280-024-04717-wopenalex-snapshot

A comparison of the renal function biomarkers serum creatinine, pro-enkephalin and cystatin C to predict clearance of pemetrexed

inferred← citeshttps://doi.org/10.1007/s00280-024-04744-7openalex-snapshot

Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans

inferred← citeshttps://doi.org/10.1007/s00292-020-00831-7openalex-snapshot

Anwendungen der FISH in der Diagnostik von Lungenkarzinomen

inferred← citeshttps://doi.org/10.1007/s00330-017-4756-5openalex-snapshot

Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer

inferred← citeshttps://doi.org/10.1007/s00330-020-06700-4openalex-snapshot

Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know

inferred← citeshttps://doi.org/10.1007/s00330-020-06784-yopenalex-snapshot

Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma

inferred← citeshttps://doi.org/10.1007/s00330-020-07624-9openalex-snapshot

A PET/CT nomogram incorporating SUVmax and CT radiomics for preoperative nodal staging in non-small cell lung cancer

inferred← citeshttps://doi.org/10.1007/s00408-019-00213-8openalex-snapshot

Bronchoscopic Brushing from Central Lung Cancer—Next Generation Sequencing Results are Reliable

inferred← citeshttps://doi.org/10.1007/s00408-019-00250-3openalex-snapshot

A Prognostic Score for Brain Metastases of Non-small-cell Lung Cancer in the Era of Precision Medicine

inferred← citeshttps://doi.org/10.1007/s00408-021-00464-4openalex-snapshot

A Modified Calculation Improves the Accuracy of Predicted Postoperative Lung Function Values in Lung Cancer Patients

inferred← citeshttps://doi.org/10.1007/s00408-021-00474-2openalex-snapshot

White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer

inferred← citeshttps://doi.org/10.1007/s00428-016-1910-4openalex-snapshot

Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients

inferred← citeshttps://doi.org/10.1007/s00428-017-2183-2openalex-snapshot

Lung cancer as a paradigm for precision oncology in solid tumours

inferred← citeshttps://doi.org/10.1007/s00428-022-03343-2openalex-snapshot

Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management

inferred← citeshttps://doi.org/10.1007/s00428-022-03446-wopenalex-snapshot

Nationwide differences in cytology fixation and processing methods and their impact on interlaboratory variation in PD-L1 positivity

inferred← citeshttps://doi.org/10.1007/s00428-023-03702-7openalex-snapshot

Molecular diagnostics tailoring personalized cancer therapy—an oncologist’s view

inferred← citeshttps://doi.org/10.1007/s00432-011-1003-3openalex-snapshot

Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial

inferred← citeshttps://doi.org/10.1007/s00432-012-1294-zopenalex-snapshot

Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents

inferred← citeshttps://doi.org/10.1007/s00432-018-2649-xopenalex-snapshot

Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)

inferred← citeshttps://doi.org/10.1007/s00432-019-02862-xopenalex-snapshot

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

inferred← citeshttps://doi.org/10.1007/s00432-019-02944-wopenalex-snapshot

Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer

inferred← citeshttps://doi.org/10.1007/s00432-020-03267-xopenalex-snapshot

Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review

inferred← citeshttps://doi.org/10.1007/s00432-020-03284-wopenalex-snapshot

Mutational profiling of lung adenocarcinoma in China detected by next-generation sequencing

inferred← citeshttps://doi.org/10.1007/s00432-021-03517-6openalex-snapshot

Detection of circulating genetically abnormal cells using 4-color fluorescence in situ hybridization for the early detection of lung cancer

inferred← citeshttps://doi.org/10.1007/s00432-021-03766-5openalex-snapshot

Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation

inferred← citeshttps://doi.org/10.1007/s00432-021-03866-2openalex-snapshot

Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients

inferred← citeshttps://doi.org/10.1007/s00432-022-03952-zopenalex-snapshot

Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC

inferred← citeshttps://doi.org/10.1007/s00432-022-04079-xopenalex-snapshot

Liposomal formulations for lung cancer treatment in the last two decades: a systematic review

inferred← citeshttps://doi.org/10.1007/s00432-022-04258-wopenalex-snapshot

Measuring the indirect cost associated with advanced non-small cell lung cancer: a nationwide cross-sectional study in China

inferred← citeshttps://doi.org/10.1007/s00432-023-05179-yopenalex-snapshot

Implementing precision oncology for sarcoma patients: the CCCLMUmolecular tumor board experience

inferred← citeshttps://doi.org/10.1007/s00432-023-05509-0openalex-snapshot

Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis

inferred← citeshttps://doi.org/10.1007/s00432-023-05538-9openalex-snapshot

Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT

inferred← citeshttps://doi.org/10.1007/s00432-024-05828-wopenalex-snapshot

‘Plasma first’ approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma

inferred← citeshttps://doi.org/10.1007/s00508-021-01940-wopenalex-snapshot

Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer

inferred← citeshttps://doi.org/10.1007/s00520-015-3015-zopenalex-snapshot

Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic non-small cell lung cancer: a single center 10-year experience

inferred← citeshttps://doi.org/10.1007/s00520-018-4489-2openalex-snapshot

The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases

inferred← citeshttps://doi.org/10.1007/s00520-019-05179-0openalex-snapshot

“Triggers” for early palliative care referral in patients with cancer: a review of urgent unplanned admissions and outcomes

inferred← citeshttps://doi.org/10.1007/s00520-020-05459-0openalex-snapshot

Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study

inferred← citeshttps://doi.org/10.1007/s00520-020-05499-6openalex-snapshot

Exercise prescription for symptoms and quality of life improvements in lung cancer patients: a systematic review

inferred← citeshttps://doi.org/10.1007/s00520-020-05665-wopenalex-snapshot

Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate—a post hoc analysis of a randomized clinical trial

inferred← citeshttps://doi.org/10.1007/s00520-020-05880-5openalex-snapshot

Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents

inferred← citeshttps://doi.org/10.1007/s00520-021-06542-wopenalex-snapshot

Integrated palliative care: triggers for referral to palliative care in ICU patients

inferred← citeshttps://doi.org/10.1007/s00740-015-0034-9openalex-snapshot

Frühe palliative Intervention

inferred← citeshttps://doi.org/10.1007/s00740-020-00370-0openalex-snapshot

Anwendungen der FISH in der Diagnostik von Lungenkarzinomen

inferred← citeshttps://doi.org/10.1007/s00740-020-00371-zopenalex-snapshot

Molekulare therapeutische Stratifizierung des nichtkleinzelligen Lungenkarzinoms

showing the first 200 of 2608

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.